Syngene Extends Research Collaboration with Bristol Myers Squibb Through 2035

Syngene International has extended its strategic research collaboration with Bristol Myers Squibb through 2035, expanding the partnership to cover a broader range of integrated services across the drug development lifecycle. This includes discovery, translational sciences, pharmaceutical development, manufacturing, clinical trials, and data services. The collaboration, ongoing since 1998, aims to build new capabilities and infrastructure to accelerate the development and commercialization of innovative therapies worldwide, reinforcing Syngene's role as a key scientific and manufacturing partner.